Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
Article
CAS
PubMed
Google Scholar
Early Breast Cancer Trialists' Collaborative, G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.
Article
CAS
Google Scholar
Clarke M, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.
Article
CAS
PubMed
Google Scholar
Prescott J, Coetzee GA. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett. 2006;231(1):12–9.
Article
CAS
PubMed
Google Scholar
Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28(7):778–808.
Article
CAS
PubMed
Google Scholar
Kumar R, McEwan IJ. Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr Rev. 2012;33(2):271–99.
Article
CAS
PubMed
PubMed Central
Google Scholar
Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol. 1993;170(1):31–5.
Article
CAS
PubMed
Google Scholar
Brys M. Androgens and androgen receptor: do they play a role in breast cancer? Med Sci Monit. 2000;6(2):433–8.
CAS
PubMed
Google Scholar
Liao DJ, Dickson RB. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol. 2002;80(2):175–89.
Article
CAS
PubMed
Google Scholar
Park S, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;21(3):488–92.
Article
CAS
PubMed
Google Scholar
Ogawa Y, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 2008;13(5):431–5.
Article
CAS
PubMed
Google Scholar
Loibl S, et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011;130(2):477–87.
Article
CAS
PubMed
Google Scholar
Hu R, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011;17(7):1867–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Collins LC, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' health study. Mod Pathol. 2011;24(7):924–31.
Article
PubMed
PubMed Central
Google Scholar
Birrell SN, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995;52(5):459–67.
Article
CAS
PubMed
Google Scholar
Hackenberg R, et al. Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Res. 1991;51(20):5722–7.
CAS
PubMed
Google Scholar
Need EF, et al. Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor alpha in luminal breast cancer cells. Mol Endocrinol. 2012;26(11):1941–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Szelei J, et al. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology. 1997;138(4):1406–12.
Article
CAS
PubMed
Google Scholar
Goldenberg IS, et al. Combined androgen and antimetabolite therapy of advanced female breast cancer. A report of the cooperative breast cancer group. Cancer. 1975;36(2):308–10.
Article
CAS
PubMed
Google Scholar
De Amicis F, et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010;121(1):1–11.
Article
CAS
PubMed
Google Scholar
Rahim B, O'Regan R. AR Signaling in Breast Cancer. Cancers (Basel). 2017;9(3).
Article
PubMed Central
CAS
Google Scholar
Gucalp A, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast Cancer. Clin Cancer Res. 2013;19(19):5505–12.
Article
CAS
PubMed
PubMed Central
Google Scholar
Traina TA, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast Cancer. J Clin Oncol. 2018;36(9):884–90.
Article
CAS
PubMed
PubMed Central
Google Scholar
Traina T, T., KM., Denise AY., Joyce O'Shaughnessy, JC., Ahmad A., Catherine MK., Maureen ET., Peter S., Luca Gianni, LG., Rita N., Foluso OA., Stephen C., Joyce LS., Martha EB., Iulia CT., Hirdesh Uppal, ACP., Clifford AH., Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). . 2015 ASCO annual meeting; 2014; Chicago, IL.
Bidard FC, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014.
Pantel K, Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res. 2013;73(21):6384–8.
Article
CAS
PubMed
Google Scholar
Schramm A, et al. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch Gynecol Obstet. 2016;293(2):271–81.
Article
CAS
PubMed
Google Scholar
Fehm T, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010;124(2):403–12.
Article
CAS
PubMed
Google Scholar
Krawczyk N, et al. Liquid biopsy in metastasized breast Cancer as basis for treatment decisions. Oncol Res Treat. 2016;39(3):112–6.
Article
CAS
PubMed
Google Scholar
Fujii T, et al. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS One. 2017;12(9):e0185231.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kalinsky K, et al. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. Clin Transl Oncol. 2015;17(7):539–46.
Article
CAS
PubMed
PubMed Central
Google Scholar
Babayan A, et al. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One. 2013;8(9):e75038.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pestrin M, et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat. 2009;118(3):523–30.
Article
CAS
PubMed
Google Scholar
Wallwiener M, et al. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer. 2015;15:403.
Article
PubMed
PubMed Central
Google Scholar
Rocca, A., et al., Is androgen receptor useful to predict the efficacy of anti-estrogen therapy in advanced breast cancer? 2017.
Book
Google Scholar
He J, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012;29(2):406–10.
Article
CAS
PubMed
Google Scholar
Safarpour D, Pakneshan S, Tavassoli FA. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res. 2014;4(4):353–68.
PubMed
PubMed Central
Google Scholar
Reyes EE, et al. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med. 2014;12:313.
Article
PubMed
PubMed Central
CAS
Google Scholar
Georget V, et al. Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor. Mol Cell Endocrinol. 1997;129(1):17–26.
Article
CAS
PubMed
Google Scholar
Nakauchi H, et al. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines. J Histochem Cytochem. 2007;55(6):535–44.
Article
CAS
PubMed
Google Scholar
Wetherill YB, et al. The xenoestrogen bisphenol a induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol Cancer Ther. 2002;1(7):515–24.
CAS
PubMed
Google Scholar
Bhasin S, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham heart study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96(8):2430–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Haring R, et al. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2012;97(2):408–15.
Article
CAS
PubMed
Google Scholar
Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res. 2009;11(5):212.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kyvernitakis I, et al. Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer. Climacteric. 2015;18(1):63–8.
Article
CAS
PubMed
Google Scholar
Eisermann K, et al. Androgen receptor gene mutation, rearrangement, polymorphism. Transl Androl Urol. 2013;2(3):137–47.
PubMed
PubMed Central
Google Scholar
Jenster G, et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol. 1991;5(10):1396–404.
Article
CAS
PubMed
Google Scholar
Koryakina Y, Knudsen KE, Gioeli D. Cell-cycle-dependent regulation of androgen receptor function. Endocr Relat Cancer. 2015;22(2):249–64.
Article
CAS
PubMed
PubMed Central
Google Scholar
Adams DL, et al. Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas. Breast Cancer Res. 2016;18(1):44.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kumar, V., Yu, J., Phan, V., Tudor, I. C., Peterson, A, Uppal, H., Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer. DOI: https://doi.org/10.1200/PO.17.00075 JCO Precision Oncology - published online October 10, 2017, 2017.